data

STL’s subsidiary announces supply agreement valued over $1Bn with a Hyperscaler for AI-Ready Data Center build-outs

MUMBAI, India, May 22, 2026 /PRNewswire/ -- Sterlite Technologies Limited ("STL") (NSE: STLTECH), a connectivity solutions provider of optical fibers, optical…

2 days ago

Relativity Adds Collection of Claude Enterprise Data with Claude Compliance API Integration

News Summary:Relativity integrates the Claude Compliance API to enable the collection of Claude Enterprise activity in RelativityOne.RelativityOne enables native collection…

2 days ago

Why Data Analytics Projects Fail Without Business Alignment

PRINCETON, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Enterprises have poured significant budgets into data analytics — bigger teams, better…

4 days ago

THE AI REALITY CHECK: DRUID AI PRODUCTION DATA REVEALS THE GAP BETWEEN AI HYPE AND ENTERPRISE ADOPTION

The first in an annual series, the report examines real-world outcomes of live AI agents across healthcare, higher education, financial…

4 days ago

Amphiform Raises $5.5M Led by General Catalyst and Main Object to Solve Energy Bottlenecks for Data Centres, Space and Defence

OXFORD, United Kingdom and SAN FRANCISCO, May 19, 2026 (GLOBE NEWSWIRE) -- Amphiform, a deep tech company building a new…

6 days ago

Design Therapeutics to Host Investor Webcast to Review Data from RESTORE-FA Trial of DT-216P2 for Friedreichs Ataxia on Monday, May 18, 2026

May 17, 2026 16:00 ET  | Source: Design Therapeutics, Inc. CARLSBAD, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- Design Therapeutics,…

7 days ago

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep…

7 days ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically significant sustained duration of effect…

1 week ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract urothelial cancer (UTUC) who completed…

1 week ago

Imviva Biotech Presents Data Demonstrating Durable Clinical Responses from Ongoing Phase 1/2 Study of CTA313 in Systemic Lupus Erythematosus at ASGCT 2026

100% of patients treated with CTA313 achieved an SRI-4 response, with half achieving remission May 14, 2026 11:43 ET  |…

1 week ago